Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Role of Sleep in Protecting Spatial Memories From Age-Related Decline

10 novembre 2026 aggiornato da: Eitan Schechtman, University of California, Irvine

Healthy aging is characterized by impaired spatial memory compared to younger adults. These impairments not only negatively impact quality of life but are also an early marker for the onset of dementia, especially Alzheimer's Disease. While sleep plays an active role in spatial memory consolidation in young adults, the extent to which sleep contributes to this process in aged adults is yet to be determined. The objective of this developmental R21 project is to determine the impact of sleep on spatial memory in cognitively healthy, aged adults, and evaluate the potential for a sleep intervention targeting memory reactivation to improve performance in this population. The project will include a single experiment using an ecologically valid ambulatory virtual environment to test the effects of sleep on spatial memory performance in aged adults.

Aim 1 will determine whether post-learning sleep benefits spatial memory in aged adults, more so than a period of wakefulness. Spatial memory performance will be measured using well-established tasks in a virtual environment, before and after a 90-minute delay consisting of either an EEG-monitored nap or wakefulness. Changes in performance between these two conditions will be measured after the 90-minute delay and again one week later. The key hypothesis for this aim is that post-learning sleep will improve spatial memory recall more than an equivalent period of wakefulness, and that this improvement will correlate with sleep stages and EEG waveforms that are linked with memory consolidation.

Aim 2 will test whether targeted memory reactivation, a technique used to bias memory consolidation by obtrusively presenting sounds during sleep, can be used to enhance spatial memory in aged adults. To this end, task-related sounds will be presented to participants during a nap immediately after learning and during nocturnal sleep over the following week. Spatial memory performance will be compared between this group and a sleep group for which no sounds will be presented during sleep. The key hypotheses are that this manipulation will improve spatial memory performance, and that these behavioral effects will be mediated by memory-related EEG waveforms elicited by sounds presented during sleep.

By combining sleep, high-density electrophysiology, and a realistic testing environment, this project will determine the benefit of sleep on spatial memory in aged adults and test ways to leverage sleep to make consolidation more efficient. Results will inform our understanding of sleep-dependent consolidation in aged adults and pave the way for scalable, non-invasive treatments to improve day-to-day life and provide critical protections against dementia.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

126

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Eitan Schechtman-Drayman
  • Numero di telefono: 847-722-9220
  • Email: eitans@uci.edu

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

60 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion:

  1. Age >=60.
  2. Montreal Cognitive Assessment score above 25.
  3. Good general health with no disease or conditions expected to interfere with the study.
  4. Fluent in English.
  5. Fully ambulatory without the use of a cane, walker, or wheelchair.
  6. Believe they will be able to fall asleep in a lab setting for an afternoon nap.

Exclusion:

  1. No history or current diagnosis of psychiatric disorders.
  2. No history or current neurological disease.
  3. No current sleep disorder, including sleep apnea and insomnia.
  4. No snoring during sleep.
  5. No uncorrected hearing, visual or motor impairment.
  6. No changes in medication usage over the past month and no plans to make such changes over the course of the study.

All inclusion/exclusion criteria, except for the Montreal Cognitive Assessment, will be based on self-report.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Wake group

Participants watch a feature-length film ("Stand By Me") in the study room for 90 minutes. They are instructed to remain awake and alert throughout. The experimenter monitors wakefulness from the control room via a baby monitor and a real-time EEG display. If EEG signs of non-rapid-eye-movement-sleep (NREM) Stage 1 or deeper sleep onset are observed, the participant is prompted to remain awake.

Comparatore attivo: Sleep group

Participants are given a 90-minute nap opportunity in a darkened sleep room (bed, clean linens, blanket) with low-volume white noise delivered via earphones. EEG (electroencephalography) with EOG (electrooculography) and EMG (electromyography) is recorded continuously. During NREM sleep, auditory cues that are unrelated to the virtual reality (VR) task are delivered. Once the experimenter confirms via real-time EEG that the participant is in NREM Stage 2 or Stage 3 sleep, non-task-associated auditory cues are delivered via a speaker at a volume calibrated individually during a Sound Volume Test before the nap - the lowest volume at which the participant can reliably detect the sound while awake. Following the nap, participants may shower or wash up in a private room with a sink.

This group will be allowed to sleep shortly after learning.

Sperimentale: Sleep+TargetedMemoryReactivation (TMR) Group

Participants follow the same nap protocol as the Sleep group, except that task-relevant sounds are presented during sleep. A minimum of 6 successful cue presentations during the nap is required for inclusion in TMR-specific analyses.

This group will be allowed to sleep shortly after learning.

The researchers will unobtrusively and repeatedly present a sound that was linked with a spatial task during sleep. This method was shown to improve memory in various tasks. The sounds will be presented both in the lab and at home. In both cases, the sounds will be presented during non-REM sleep stages 2 and 3. The sounds will only be presented to the Sleep+TMR group (N = 42).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Performance on spatial memory task - wayfinding task
Lasso di tempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Accuracy will be measured (percent of correct trials)

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week
Performance on spatial memory task - pointing task
Lasso di tempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Angular error will be measured (averaged over trials)

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Performance on other memory tasks - paired-associates task
Lasso di tempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

The researchers will use the paired-associates task to examine the effects of sleep on declarative memories. Percent correct pairs will be used.

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week
Performance on other memory tasks - serial reaction time task
Lasso di tempo: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

The researchers will use the serial reaction time task to examine the effects of sleep on non-declarative memories. The number of correct sequences will be used.

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

5 novembre 2026

Completamento primario (Stimato)

31 marzo 2028

Completamento dello studio (Stimato)

31 marzo 2028

Date di iscrizione allo studio

Primo inviato

29 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 7502
  • R21AG101676 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All datasets that can be shared will be deposited in OpenNeuro, which is an NIH-supported free and open platform for validating and sharing data. De-identified behavioral data, task programs and code, analysis code, experimental protocols, and any additional metadata will be stored and shared on the Open Science Framework. Additional code will be available on GitHub.

Periodo di condivisione IPD

Shared data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the end of the funding period.

Criteri di accesso alla condivisione IPD

There are no anticipated factors or limitations that will affect the access, distribution or reuse of the scientific data generated by the proposal.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .